Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

FDA presses its campaign against rogue regenerative med players, cites StemGenex for illegal sales

7 years ago

Sarepta shares sink on the back of a monster $500M raise

7 years ago

Gene therapy developer Orchard prices IPO at $14 to raise $200M

7 years ago

Spark's CSO is wrapping up animal studies on a gene therapy for Pompe disease as new work in the field sees explosive growth

7 years ago

Avrobio shares blasted after trial update sours outlook on gene therapy for Fabry disease

7 years ago

Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects

7 years ago

Novartis drums up EU launch plans as CHMP gives thumbs up to Spark's gene therapy Luxturna

7 years ago

Amicus CEO Crowley bags a gene therapy company, a new pipeline — and a great photo op — for $100M in cash

7 years ago

Analyst offers Amgen a boost for its rival anti-BCMA BiTE, blemishing GSK as well as CAR-T rivals Celgene and bluebird

7 years ago

A knockdown-and-replace gene therapy from Penn researchers shows promise in rare eye disease

7 years ago

FDA, NIH look to streamline oversight of gene therapies

7 years ago

Mustang Bio ventures into gene therapy, licensing 'bubble boy disease' treatment from St. Jude

7 years ago

Fresh from hauling in GSK’s budget-priced gene therapy group, Orchard harvests $150M mega-round. Is it time to IPO?

7 years ago

Astellas grabs a biotech toddler in $109M buyout deal for a glaucoma gene therapy program

7 years ago

FDA lays down the law on gene therapy, offering guidances on both diseases and procedures

7 years ago

Parker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells

7 years ago

Penn team-biotech collaboration highlights promise of gene editing in targeting PCSK9, liver diseases

7 years ago

Sarepta leads off Duchenne MD gene therapy study with a ‘home run’ on efficacy — but can they deliver in 2 years?

7 years ago

Determined to build the leading biotech player in a new R&D space, Steven Holtzman lines up $55M for the next stage at Decibel

7 years ago

Solid Bio is back in business after the FDA lifts clinical hold on Duchenne MD gene therapy

7 years ago

Nightstar's drug for rare vision loss admitted to FDA's gene therapy speedway

7 years ago

CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front

7 years ago

FDA chief Gottlieb is building a regulatory speedway to accelerate gene therapy development

7 years ago

Is biopharma’s first $1.5M therapy now in Phase III?

8 years ago

First page Previous page 53 54 555657 58 Next page Last page